Oncotelic Therapeutics Launched BIO REBOOT Platform
The biotech firm introduced an AI-driven tool for researchers to identify scientific hypotheses.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Do you believe artificial intelligence integration will significantly accelerate major medical research breakthroughs?
Oncotelic Therapeutics has launched the BIO REBOOT collaboration platform for scientists and developers. The initiative utilizes the PDAOAI platform to help collaborators convert ideas into testable scientific discoveries.
Why it matters
The program provides a centralized environment for researchers to develop oncology and immunotherapy products. Oncotelic may consider selected projects from the collaboration for future startup funding and development support.
The PDAOAI platform utilizes a Partitioned Literature Aggregation method to map biomedical literature into a high-dimensional vector space. The index includes 29 million PubMed abstracts, with 4.4 million of those organized into disease-specific groups.
The players
Oncotelic Therapeutics
An Agoura Hills, California-based developer of oncology and immunotherapy products.
Scott Myers
A featured keynote presenter scheduled for the Drug Discovery 2026 conference.
Saran Saund
A scheduled keynote presenter and panelist at the Drug Discovery 2026 conference.
Pet2DAO
A wholly owned subsidiary organization operating under the Oncotelic Therapeutics corporate umbrella.
The details
The PDAOAI platform analyzes specific literature groups to identify potential research hypotheses for developers. Interested collaborators can participate in the BIO REBOOT program for free to leverage these data insights.
Timeline
October 7, 2026: Scott Myers will deliver a keynote presentation at the Drug Discovery 2026 conference.
October 8, 2026: Saran Saund will present and participate in a panel discussion at the conference.
October 7-9, 2026: The Drug Discovery 2026 conference will take place in Burlingame, California.
The Tech Race
The launch of the PDAOAI platform follows a broader industry trend of integrating vector-based AI search tools into academic research workflows. This initiative represents a shift toward automating early-stage hypothesis generation in oncology and immunotherapy development.
Researchers and developers can now access the BIO REBOOT program for free to streamline their experimental research. This platform reduces the manual effort required to aggregate and analyze millions of biomedical abstracts for new therapy development.
The takeaway
The use of large-scale AI indexing marks a transition toward data-heavy hypothesis testing in pharmaceutical research. Developers aiming to innovate in the oncology sector may leverage these tools to speed up their discovery timelines.
What happens next
Keynote presentations are scheduled at the Drug Discovery 2026 conference in Burlingame, California, beginning October 7, 2026.
Further reading
For more on the industry, visit the Biotech section.
More information
To register for the platform, visit the BIO REBOOT program registration portal.
Live Poll
Do you believe artificial intelligence integration will significantly accelerate major medical research breakthroughs?
